Major Depressive Disorder Clinical Trial
Official title:
Study of tDCS Intervention on Motivational Anhedonia of Major Depressive Disorder
NCT number | NCT04425278 |
Other study ID # | Yu |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | March 1, 2018 |
Est. completion date | December 31, 2021 |
Study of tDCS intervention on motivational anhedonia of Major Depressive Disorder
Status | Recruiting |
Enrollment | 90 |
Est. completion date | December 31, 2021 |
Est. primary completion date | December 31, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 60 Years |
Eligibility |
Inclusion Criteria: 1. Meet criteria of depression assessed by at least two psychiatrists according to the five version of Diagnostic and Statistical Manual of Mental Disorders. 2. The score of Hamilton Depression Rating Scale-17 was larger than 18. 3. Patients were taking antidepressants--Selective Serotonin Reuptake Inhibitor(SSRIs) alone. 4. Age was between 18 to 60 year old. 5. The education duration was at least 6 years. 6. The vision or corrected vision was normal. 7. Right handedness. 8. No treatment of rTMS, transcranial direct current stimulation or electroconvulsive therapy before. Exclusion Criteria: 1. History of significant head trauma or neurological disorders. 2. Alcohol or drug abuse. 3. Focal brain lesions. 4. History of seizure. 5. First degree relative with epilepsy, significant neurological illness or head trauma, endocrine disease. 6. Significant unstable medical condition. 7. Recent aggression or other forms of behavioral dyscontrol. 8. Left-handedness. 9. Pregnancy. 10. Current alcohol or drug abuse 11. Inability to provide informed consent. 12. Patients with contraindications or factors affecting imaging quality, such as pacemakers, cochlear implants, or hearts Cerebrovascular metal stent, and metal denture. |
Country | Name | City | State |
---|---|---|---|
China | Anhui Medical University | Hefei | Anhui |
Lead Sponsor | Collaborator |
---|---|
Anhui Medical University |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change from baseline in Hamilton Depression Scale | The participants' depression symptom assessed by the Hamilton Depression Scale change from baseline after the treatment. | baseline;14 day post-treatment | |
Primary | Change from baseline in Motivation and Pleasure Scale | The severity of participants' anhedonia assessed by the Motivation and Pleasure Scale change from baseline after the treatment. | baseline;14 day post-treatment | |
Secondary | The change from baseline in behavioral results of Monetary Incentive Delay task | The motivational anhedonia assessed by accuracy and response time in Monetary Incentive Delay task | baseline; 14 day post-treatment change from baseline after the treatment. | |
Secondary | The change from baseline in event-related brain potentials during the monetary incentive delay task | The amplitudes of brain potentials of contingent negative variation and P3 assessed by event-related brain potentials methods change from baseline after the treatment. | baseline; 14 day post-treatment |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05537558 -
Precision Medicine for the Prediction of Treatment (PROMPT) Response (PROMPT)
|
||
Terminated |
NCT02192099 -
Open Label Extension for GLYX13-C-202, NCT01684163
|
Phase 2 | |
Completed |
NCT03142919 -
Lipopolysaccharide (LPS) Challenge in Depression
|
Phase 2 | |
Recruiting |
NCT05547035 -
Identification of Physiological Data by a Wearable Monitor in Subjects Suffering From Major Depression Disorders
|
N/A | |
Terminated |
NCT02940769 -
Neurobiological Effects of Light on MDD
|
N/A | |
Recruiting |
NCT05892744 -
Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression
|
Phase 4 | |
Recruiting |
NCT05537584 -
SMART Trial to Predict Anhedonia Response to Antidepressant Treatment
|
Phase 4 | |
Active, not recruiting |
NCT05061706 -
Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
|
Phase 3 | |
Completed |
NCT04479852 -
A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder
|
Phase 2 | |
Recruiting |
NCT04032301 -
Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans
|
Phase 1 | |
Recruiting |
NCT05527951 -
Enhanced Measurement-Based Care Effectiveness for Depression (EMBED) Study
|
N/A | |
Completed |
NCT03511599 -
Cycloserine rTMS Plasticity Augmentation in Depression
|
Phase 1 | |
Recruiting |
NCT04392947 -
Treatment of Major Depressive Disorder With Bilateral Theta Burst Stimulation
|
N/A | |
Recruiting |
NCT05895747 -
5-HTP and Creatine for Depression R33 Phase
|
Phase 2 | |
Recruiting |
NCT05273996 -
Predictors of Cognitive Outcomes in Geriatric Depression
|
Phase 4 | |
Recruiting |
NCT05813093 -
Interleaved TMS-fMRI in Ultra-treatment Resistant Depression
|
N/A | |
Recruiting |
NCT05135897 -
The Neurobiological Fundaments of Depression and Its Relief Through Neurostimulation Treatments
|
||
Enrolling by invitation |
NCT04509102 -
Psychostimulant Augmentation of Repetitive TMS for the Treatment of Major Depressive Disorder
|
Early Phase 1 | |
Recruiting |
NCT06026917 -
Assessing Dopamine Transporter Occupancy in the Patients With Depression Brain With Toludesvenlafaxine Hydrochloride Extended-Release Tablets Using 11C-CFT Positron Emission Tomography (PET)
|
Phase 4 | |
Recruiting |
NCT06145594 -
EMA-Guided Maintenance TMS for Depression
|
N/A |